Biomarkers of response to immune checkpoint blockade in cancer treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Biomarkers of response to immune checkpoint blockade in cancer treatment

Published:2018-10 Issue: Volume:130 Page:108-120
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Fujii Takeo,Naing Aung,Rolfo Christian^ORCID,Hajjar Joud^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference148 articles.

1. The tumour microenvironment as a target for chemoprevention;Albini;Nat. Rev. Cancer,2007

2. Signatures of mutational processes in human cancer;Alexandrov;Nature,2013

3. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer;Angell;Curr. Opin. Immunol.,2013

4. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay;Baccelli;Nat. Biotechnol.,2013

5. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial;Balar;Lancet,2017

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer;Diseases;2024-05-02

2. The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK;International Journal of Cancer;2024-04-29

3. All-Rounder Liposomes in Cancer Immunotherapy: Strategies and Design Applications of Engineered Liposomal Nanomaterials;BioChip Journal;2024-04-03

4. PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer;Translational Lung Cancer Research;2024-02

5. Efficacy and Safety of Atezolizumab Monotherapy or Combined Therapy with Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Current Pharmaceutical Design;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3